Wealth Enhancement Advisory Services
ORMP icon

Wealth Enhancement Advisory Services’s Oramed Pharmaceuticals ORMP Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$67.4K Buy
16,042
+3,147
+24% +$14.2K ﹤0.01% 4001
2026
Q2 		$52.1K Sell
12,895
-604
-4% -$2.4K ﹤0.01% 3910
2026
Q1 		$46.2K Sell
13,499
-4,800
-26% -$16.3K ﹤0.01% 3438
2025
Q4 		$56.2K Sell
18,299
-500
-3% -$1.29K ﹤0.01% 3526
2025
Q3 		$46.6K Hold
18,799
– – ﹤0.01% 3439
2025
Q2 		$41K Buy
18,799
+5,000
+36% +$11K ﹤0.01% 3247
2025
Q1 		$29.5K Hold
13,799
– – ﹤0.01% 2891
2024
Q4 		$33.4K Buy
13,799
+2,499
+22% +$5.94K ﹤0.01% 2886
2024
Q3 		$27.6K Sell
11,300
-100
-0.9% -$244 ﹤0.01% 2654
2024
Q2 		$29.3K Hold
11,400
– – ﹤0.01% 2472
2024
Q1 		$33.3K Sell
11,400
-500
-4% -$1.4K ﹤0.01% 2362
2023
Q4 		$27.5K Hold
11,900
– – ﹤0.01% 2241
2023
Q3 		$31.1K Buy
+11,900
New +$37.5K ﹤0.01% 2180

Other funds holding ORMP

Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
SCM
Sage Capital Management Stockton, New Jersey $263M AUM 22.29% 1-Year Est. Return
Redwood Family Wealth
Redwood Family Wealth Addison, Texas $113M AUM 24.54% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Wealth Enhancement Advisory Services's ORMP Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Oramed Pharmaceuticals (ORMP) stake by 24% in Q3 2026, buying an estimated $14.2K and bringing the position to 16,042 shares worth $67.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4001.

Wealth Enhancement Advisory Services first reported a position in ORMP in Q3 2023 and has held it in 13 quarters since. 8 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

  • Wealth Enhancement Advisory Services held 16,042 shares of Oramed Pharmaceuticals worth $67.4K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 3,147 Oramed Pharmaceuticals shares in Q3 2026, an estimated $14.2K.
  • Oramed Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4001 holding.
  • Wealth Enhancement Advisory Services first reported a position in Oramed Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
  • 8 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.